retatrutide peptide trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II Retatrutide, an investigational triple hormone

Challenges : Regulatory scrutiny around efficacy claims

And while weight loss is often part of the conversation, its rarely the whole story

The observed reduction in AUD risk is particularly noteworthy given the global burden of AUD, which affects an estimated 280 million people and is associated with high morbidity and mortality [34]

The goal is to deposit the medication in the middle of the fat layer, not too shallow (which causes leakage) and not too deep (which hits muscle)

meta-analysis: OR = 0.72, 95% CI [0.610.86]), anxiety disorders (FinnGen: OR = 0.81, 95% CI [0.760.87]

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus